Novartis AG To Go Ex-Dividend On March 12th, 2025 With 3.86954 USD Dividend Per Share

Moomoo NewsMar 10 21:00 ET

Express News | 'Novartis Sees Radioactive Cancer Drugs Becoming $10B Business: CEO' - Nikkei Asia

BenzingaMar 10 15:47 ET

Weight-loss Drug Battle: Who Are the Latest Players Involved

Seeking AlphaMar 8 13:30 ET

Top Gap Ups and Downs on Friday: COST, NVS, ISRG and More

Moomoo NewsMar 7 18:00 ET · Markets

Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss

BenzingaMar 6 11:29 ET

Novartis (NVS.US) BTK inhibitors are proposed for priority review in China for the treatment of urticaria.

Public data shows that remibrutinib is a BTK inhibitor under investigation by Novartis, and the initial indication for this product is the treatment of chronic spontaneous urticaria.

Zhitong FinanceMar 6 08:16 ET